Eli Lilly and Company $LLY Stock Purchased by Gerber Kawasaki Wealth & Investment Management

Key Points

• Gerber Kawasaki increased its Eli Lilly stake by 12.6% in the third quarter, adding 2,139 shares to hold 19,169 shares valued at about $22.18 million. Other institutional investors also reported adding shares.
• Lilly reported quarterly revenue of $24.4 billion, up 38.6% year over year, and EPS of $7.48, beating estimates for both. The company also raised its 2026 revenue outlook to $91 billion–$92 billion.
• Insiders sold 18,500 shares worth about $22.97 million over three months; the disclosed executive sales were conducted under pre-arranged Rule 10b5-1 plans. Analysts’ consensus rating is “Moderate Buy,” with a consensus price target of $1,404.14.

Gerber Kawasaki Wealth & Investment Management boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 12.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,169 shares of the company's stock after acquiring an additional 2,139 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Eli Lilly and Company were worth $22,180,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in LLY. Torren Management LLC boosted its holdings in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company's stock valued at $37,000 after purchasing an additional 25 shares in the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC increased its stake in Eli Lilly and Company by 5.0% in the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 8,646 shares of the company's stock valued at $10,004,000 after purchasing an additional 414 shares during the last quarter. Blue Bell Private Wealth Management LLC raised its holdings in Eli Lilly and Company by 22.4% during the third quarter. Blue Bell Private Wealth Management LLC now owns 715 shares of the company's stock worth $827,000 after purchasing an additional 131 shares in the last quarter. Frederick Financial Consultants LLC raised its holdings in Eli Lilly and Company by 9.2% during the third quarter. Frederick Financial Consultants LLC now owns 213 shares of the company's stock worth $247,000 after purchasing an additional 18 shares in the last quarter. Finally, Signature Equity Partners LLC raised its holdings in Eli Lilly and Company by 35.2% during the third quarter. Signature Equity Partners LLC now owns 987 shares of the company's stock worth $1,142,000 after purchasing an additional 257 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company's stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 18,500 shares of company stock worth $22,970,770. 0.14% of the stock is owned by company insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,408.68 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm has a market cap of $1.33 trillion, a PE ratio of 45.72, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company's 50 day simple moving average is $1,204.03 and its 200-day simple moving average is $1,095.92. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 EPS. Eli Lilly and Company's revenue for the quarter was up 38.6% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 35.61 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's payout ratio is currently 22.46%.

Analyst Ratings Changes

Several research analysts have recently issued reports on LLY shares. Bank of America restated a "buy" rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a report on Friday. Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research report on Friday, September 18th. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research note on Monday. Leerink Partners boosted their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an "outperform" rating in a research report on Wednesday, October 21st. Finally, HSBC upped their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.